Jounce Therapeutics (JNCE) and Its Competitors Head to Head Comparison

Jounce Therapeutics (NASDAQ: JNCE) is one of 295 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its peers? We will compare Jounce Therapeutics to related companies based on the strength of its valuation, earnings, analyst recommendations, institutional ownership, risk, dividends and profitability.


This table compares Jounce Therapeutics and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Jounce Therapeutics -2.03% -1.39% -0.50%
Jounce Therapeutics Competitors -5,292.12% -108.98% -37.44%

Valuation & Earnings

This table compares Jounce Therapeutics and its peers gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Jounce Therapeutics $37.20 million -$13.70 million -141.47
Jounce Therapeutics Competitors $275.31 million -$22.88 million 86.29

Jounce Therapeutics’ peers have higher revenue, but lower earnings than Jounce Therapeutics. Jounce Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a summary of recent recommendations for Jounce Therapeutics and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Jounce Therapeutics 0 0 4 0 3.00
Jounce Therapeutics Competitors 1270 3676 12229 264 2.66

Jounce Therapeutics presently has a consensus price target of $29.00, indicating a potential upside of 20.58%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 41.07%. Given Jounce Therapeutics’ peers higher probable upside, analysts plainly believe Jounce Therapeutics has less favorable growth aspects than its peers.

Insider & Institutional Ownership

87.8% of Jounce Therapeutics shares are owned by institutional investors. Comparatively, 50.3% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 16.9% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.


Jounce Therapeutics beats its peers on 7 of the 12 factors compared.

Jounce Therapeutics Company Profile

Jounce Therapeutics, Inc. is a clinical stage immunotherapy company. The Company is engaged in transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient. The Company’s lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates Inducible T cell CO-Stimulator (ICOS) and is in a Phase II trial.

Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit